Side Effects of glecaprevir and pibrentasvir: A Synthesis of Findings from 13 Studies

  1. Home
  2. Side Effects of glecaprevir and pibrentasvir
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of glecaprevir and pibrentasvir: A Synthesis of Findings from 13 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of glecaprevir and pibrentasvir: A Synthesis of Findings from 13 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Glecaprevir and pibrentasvir combination therapy has been shown to be effective in treating chronic hepatitis C, with high rates of sustained virological response (SVR) and a favorable safety profile. 4 , 13 This drug has demonstrated efficacy against various hepatitis C virus genotypes. 10 , 7 Moreover, effectiveness and safety have been confirmed in patients with renal impairment and older adults. 11 , 4 Furthermore, it has been suggested that the drug may be effective in patients with drug resistance. 9 However, the occurrence of side effects is possible. 9 , 3

Reasons for Side Effects

The side effects of glecaprevir and pibrentasvir combination therapy are thought to be related to the drug's action on the liver, suppressing the virus. 10 The severity of side effects can vary depending on the dosage and individual patient's constitution. 12

Common Side Effects

Gastrointestinal

The most common side effect of glecaprevir and pibrentasvir combination therapy is gastrointestinal symptoms. 9 Constipation, diarrhea, nausea, and abdominal pain have been reported. 3

Hematologic

In rare cases, hematologic side effects such as anemia and thrombocytopenia have been reported. 6

Hepatic

Hepatic dysfunction has been reported. 7

Skin

Skin rash and pruritus have been reported. 3

Other

Fatigue, headache, and dysgeusia have been reported. 2

Countermeasures for Side Effects

Gastrointestinal Side Effects

For gastrointestinal side effects, measures such as dietary therapy and medication may be considered. 9

Hematologic Side Effects

If hematologic side effects are observed, drug administration should be discontinued, and appropriate treatment should be provided. 6

Hepatic Side Effects

If hepatic dysfunction is observed, drug administration should be discontinued, and appropriate treatment should be provided. 7

Skin Side Effects

For skin side effects, medication such as antihistamines may be effective. 3

Other Side Effects

Appropriate treatment is required for other side effects. 2

Comparison Between Studies

Commonalities in Studies

Multiple studies have shown that glecaprevir and pibrentasvir combination therapy is effective in treating chronic hepatitis C. 10 , 9 , 4 , 6

Differences in Studies

The frequency and severity of side effects vary depending on the study. 9 , 3 This is thought to be influenced by factors such as the age, condition, and drug dosage of the study subjects. 12

Points to Note Regarding Application in Real Life

Glecaprevir and pibrentasvir combination therapy is an effective drug for the treatment of chronic hepatitis C. 10 However, as there is a possibility of side effects, it is important to take it according to your doctor's instructions. 2 Also, the efficacy and side effects of the drug may vary depending on the patient. 12 Therefore, it is important to consult with your doctor and choose the appropriate treatment method for your condition. 8

Limitations of Current Research

Research on the side effects of glecaprevir and pibrentasvir combination therapy is still insufficient. 2 In particular, research on long-term side effects and side effects in patients with specific constitutions is lacking. 12

Future Research Directions

Further research is needed on the long-term safety and side effects of glecaprevir and pibrentasvir combination therapy in patients with specific constitutions. 12 Development of new treatments to reduce drug side effects is also necessary. 3

Conclusion

Glecaprevir and pibrentasvir combination therapy is an effective drug for the treatment of chronic hepatitis C. 10 However, as there is a possibility of side effects, it is important to take it according to your doctor's instructions. 2 The efficacy and side effects of the drug may vary depending on the patient. 12 Therefore, it is important to consult with your doctor and choose the appropriate treatment method for your condition. 8

Literature analysis of 13 papers
Positive Content
13
Neutral Content
0
Negative Content
0
Article Type
1
0
0
1
13
1.

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice.

Author: Gonzalez-SernaAlejandro, Corma-GomezAnaïs, TellezFrancisco, Corona-MataDiana, Rios-VillegasMaría Jose, MerinoDolores, GaleraCarlos, Collado-RomachoAntonio Ramon, De Los SantosIgnacio, CucurullJosep, SantosMarta, García-MartínSofía, RiveroAntonio, RealLuis Miguel, MaciasJuan

Effective HCV treatment
Tolerable therapy
Active drug use

This study compared the sustained viral response (SVR) rates of glecaprevir/pibrentasvir (G/P) in HIV/HCV-coinfected and HCV-monoinfected patients. SVR rates were similar in both groups (95.5% vs 95.1%), highlighting the effectiveness of G/P in HIV/HCV coinfection. However, active drug use was a significant barrier to achieving SVR in the HIV/HCV group.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.

Author: TsaiYu-Chi, YuMing-Lung, KoChou-Yuan, HsinYi-Hsiang, TsaiQi-Zhang, HuangChien-Wei

Hepatitis C treatment

Hepatitis C is a significant health concern in Taiwan, particularly within prisons. This study analyzed the effectiveness of hepatitis C treatment and its side effects in prison patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.

Author: PuglieseNicola, CalvarusoVincenza, MasaroneMario, D'AmbrosioRoberta, BattistellaSara, LicataAnna, PersicoMarcello, AnolliMaria Paola, DistefanoMarco, PettaSalvatore, RussoFrancesco Paolo, Di MarcoVito, AghemoAlessio

High SVR rates
Serious adverse events
Side effects

This retrospective multicentre real-world study investigated the efficacy and safety of G/P in Caucasian patients aged 75 years and older with chronic hepatitis C virus (HCV) infection. The study found that G/P achieved 97.9% SVR rates in HCV patients older than 75 years of age. Safety was optimal with only 2% of patients discontinuing early.

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

5.

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.

Author: Gonzalez-SernaAlejandro, MaciasJuan, Corma-GomezAnaïs, TellezFrancisco, CucurullJosep, RealLuis M, GranadosRafael, Rivero-JuarezAntonio, Hernandez-QueroJosé, MerinoDolores, PalaciosRosario, RiosMaria José, ColladoAntonio, PinedaJuan A

Effective treatment for HCV
Dropout

Active drug use was associated with lower sustained virological response (SVR) rates to glecaprevir/pibrentasvir (G/P) for hepatitis C treatment, mainly due to voluntary dropout.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Hepatitis C treatment at a Swedish needle exchange program, a successful model of care - the ACTIONNE study.

Author: BloméMarianne Alanko, BråbäckMartin, AlsterbergSara, JerkemanAnna

High SVR rates
NEP engagement
Lost to follow-up
Reinfection

This study evaluated the effectiveness of a needle exchange program for engaging people who inject drugs in HCV care. A high rate of sustained virological response was achieved, suggesting that needle exchange programs can serve as a useful platform for HCV management.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Hepatitis C: A Pharmacological Therapeutic Update.

Author: Santander BallestínSonia, Gómez MartínDavid, Lorente PérezSara, Luesma BartoloméMaría José

Hepatitis C treatment

This review discusses the latest advancements in hepatitis C treatment, focusing on second-generation direct-acting antivirals (DAAs). These DAAs have proven highly effective, with fewer side effects and pangenotypic action, leading to simplified treatment regimens and shorter durations. The review compares these new therapies with the World Health Organization's current recommendations.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.

Author: YapDesmond Y H, LiuKevin S H, HsuYu-Chun, WongGrace L H, TsaiMing-Chang, ChenChien-Hung, HsuChing-Sheng, HuiYee Tak, LiMichael K K, LiuChen-Hua, KanYee-Man, YuMing-Lung, YuenMan-Fung

HCV treatment

This study aimed to investigate the treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment, specifically those infected with non-1 genotype (GT) HCV.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.

Author: ChenWei-Ming, WeiKuo-Liang, TungShui-Yi, ShenChien-Heng, ChangTe-Sheng, YenChih-Wei, HsiehYung-Yu, ChiuWen Nan, HuJin Hung, LuSheng-Nan, HungChao-Hung

HCV treatment
Virological failure

This study evaluated possible predictors of virological failure and side effects of glecaprevir/pibrentasvir (GLE/PIB) therapy for chronic hepatitis C virus (HCV) genotype 2 infection in a real-world setting.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Author: AsselahTarik, KowdleyKris V, ZadeikisNeddie, WangStanley, HassaneinTarek, HorsmansYves, ColomboMassimo, CalinasFilipe, AguilarHumberto, de LedinghenVictor, MantryParvez S, HezodeChristophe, MarinhoRui Tato, AgarwalKosh, NevensFrederik, ElkhashabMagdy, KortJens, LiuRan, NgTeresa I, KrishnanPreethi, LinChih-Wei, MensaFederico J

HCV treatment
HCV genotype diversity

Glecaprevir and pibrentasvir are new drugs used to treat hepatitis C. This study evaluated the safety and effectiveness of these drugs in patients with hepatitis C genotypes 2, 4, 5, or 6. The study found that these drugs were effective in treating hepatitis C and had a good safety profile.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.